Company intelligence / Profile preview

Epi One

Brooklyn, New York, United Statesepi-one.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Epi One is developing a disruptive, highly accurate, and affordable blood-based PCR diagnostic platform for early detection of multiple cancers. The company claims its test can deliver results in as little as six hours using fewer than 10 biomarkers per test. As of 2024, the company is pre-revenue and has not yet reported clinical trial results or regulatory approvals.

Therapeutic areas: Oncology
Modalities: PCR testDNA-based biomarker identification technologyMolecular diagnostics platform
Industry: Molecular Diagnostics

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Epi One.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epi One.

Explore the full profile